LISATA THERAPEUTICS, INC. LSTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-100.26
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $170,000 | -$16.6M | — | -$16.0M | $14.9M |
| 2024 | $1.0M | -$20.0M | — | -$19.4M | $29.3M |
| 2023 | $0 | -$20.8M | — | -$20.0M | $47.9M |
| 2022 | $0 | -$54.2M | — | -$21.5M | $66.3M |
| 2021 | — | -$27.5M | — | -$22.3M | $92.0M |
| 2020 | — | -$8.2M | — | -$8.8M | $32.2M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -100.26 (distress)
- Working capital / assets 0.825
- Retained earnings / assets -31.822
- EBIT / assets -1.026
- Equity / liabilities 4.726
Source: SEC EDGAR filings · CIK 0000320017 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.